These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17090194)

  • 21. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors.
    Tse GM; Putti TC; Lui PC; Lo AW; Scolyer RA; Law BK; Karim R; Lee CS
    Mod Pathol; 2004 Jul; 17(7):827-31. PubMed ID: 15044924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of phyllodes tumor recurrence according to the histologic grade.
    Kim S; Kim JY; Kim DH; Jung WH; Koo JS
    Breast Cancer Res Treat; 2013 Oct; 141(3):353-63. PubMed ID: 24062207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome.
    Onkendi EO; Jimenez RE; Spears GM; Harmsen WS; Ballman KV; Hieken TJ
    Ann Surg Oncol; 2014 Oct; 21(10):3304-9. PubMed ID: 25034817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions.
    Chen PH; Bossuyt V; Reisenbichler E
    Hum Pathol; 2021 Feb; 108():68-75. PubMed ID: 33245988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the extent of surgical resection important in patient outcome in benign and borderline phyllodes tumors of the breast?
    Sevinç Aİ; Aksoy SÖ; Güray Durak M; Balcı P
    Turk J Med Sci; 2018 Feb; 48(1):28-33. PubMed ID: 29479947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.
    Tse GM; Chaiwun B; Lau KM; Scolyer R; Lee CS; Karim RZ; Putti TC; Law BK; Lui PC; Tan PH
    J Clin Pathol; 2007 Sep; 60(9):1051-6. PubMed ID: 17158636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.
    Cimino-Mathews A; Hicks JL; Sharma R; Vang R; Illei PB; De Marzo A; Emens LA; Argani P
    Hum Pathol; 2013 Nov; 44(11):2494-500. PubMed ID: 23916291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of cancer stem cell markers in breast phyllodes tumor.
    Kim SI; Koo JS
    Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast.
    Liu J; Liu X; Feng X; Liu J; Lv S; Zhang W; Niu Y
    Breast Cancer Res Treat; 2015 Jan; 149(2):395-401. PubMed ID: 25534827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent phyllodes tumours of the breast: pathological features and clinical implications.
    Tan EY; Tan PH; Yong WS; Wong HB; Ho GH; Yeo AW; Wong CY
    ANZ J Surg; 2006 Jun; 76(6):476-80. PubMed ID: 16768772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local Recurrence of Benign, Borderline, and Malignant Phyllodes Tumors of the Breast: A Systematic Review and Meta-analysis.
    Lu Y; Chen Y; Zhu L; Cartwright P; Song E; Jacobs L; Chen K
    Ann Surg Oncol; 2019 May; 26(5):1263-1275. PubMed ID: 30617873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast.
    Jang JH; Choi MY; Lee SK; Kim S; Kim J; Lee J; Jung SP; Choe JH; Kim JH; Kim JS; Cho EY; Lee JE; Nam SJ; Yang JH
    Ann Surg Oncol; 2012 Aug; 19(8):2612-7. PubMed ID: 22476816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of phyllodes tumours of the breast: evaluation of 66 cases and literature review].
    Lohmeyer JA; Huster N; Lühr C; Lindner C; Wittig KS; Keck MK
    Handchir Mikrochir Plast Chir; 2021 Apr; 53(2):159-167. PubMed ID: 32785910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A giant malignant phyllodes tumor of breast post mastectomy with metastasis to stomach manifesting as anemia: a case report and review of literature.
    Liu HP; Chang WY; Hsu CW; Chien ST; Huang ZY; Kung WC; Liu PH
    BMC Surg; 2020 Aug; 20(1):187. PubMed ID: 32799838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-cadherin expression in the epithelial components of mammary phyllodes tumors.
    Tsang JY; Mendoza P; Putti TC; Karim RZ; Scolyer RA; Lee CS; Pang AL; Tse GM
    Hum Pathol; 2012 Dec; 43(12):2117-23. PubMed ID: 22820000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.
    Karim RZ; Gerega SK; Yang YH; Spillane A; Carmalt H; Scolyer RA; Lee CS
    Histopathology; 2010 Jun; 56(7):868-75. PubMed ID: 20497245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
    Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
    Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of phyllodes breast tumors.
    Guillot E; Couturaud B; Reyal F; Curnier A; Ravinet J; Laé M; Bollet M; Pierga JY; Salmon R; Fitoussi A;
    Breast J; 2011; 17(2):129-37. PubMed ID: 21251125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases.
    Reinfuss M; Mituś J; Duda K; Stelmach A; Ryś J; Smolak K
    Cancer; 1996 Mar; 77(5):910-6. PubMed ID: 8608483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.